This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
To the Editor:—
We would like to comment on some aspects of the study (193:929, 1965). The treatment of control patients was not entirely comparable to that of the treated patients: (1) It appears that the control patients did not receive placebo medication, nor did they have prothrombin determinations performed regularly; (2) the control patients were examined once monthly, while the treated patients, in addition to being examined monthly, reported every one to two weeks for prothrombin determinations; (3) the physicians who treated the patients knew to which group they belonged. These differences in treatment of the two groups might have influenced the results.We are currently conducting a long-term controlled trial with anticoagulant therapy after myocardial infarction in which control patients receive an inert (placebo) pill or capsule identical in appearance to the anticoagulant medication. Prothrombin determinations are performed with equal frequency on anticoagulant-treated and non-anticoagulant-treated patients. The
Drapkin A, Merskey C. Long-Term Anticoagulants for Myocardial Infarction. JAMA. 1965;194(8):933–934. doi:10.1001/jama.1965.03090210097034